BMJ Study Finds No Link Between Maternal Sedative Use in Pregnancy and Child Psychiatric Disorders

The Largest Study of Its Kind

A groundbreaking study published in The BMJ on 29 April 2026 has found no increased risk of psychiatric or neurodevelopmental disorders in children whose mothers used sedatives during pregnancy. The research, examining nearly 3.8 million children born in South Korea between 2010 and 2022, represents the most full investigation to date into the long-term safety of benzodiazepines and Z-hypnotics during pregnancy.

Among the 3,809,949 children studied, 94,482 – representing 2.5% of all births – were exposed to these sedatives while in the womb. Researchers used South Korea’s National Health Information Database to track outcomes across 12 different psychiatric and neurodevelopmental conditions, including ADHD, autism, schizophrenia, intellectual disability, and behavioural disorders.

What the Numbers Revealed

Initial analyses appeared to show modest associations between sedative use and some psychiatric conditions in children. But these links vanished when researchers conducted sibling comparisons – a rigorous method that accounts for shared family, genetic, and environmental factors.

This approach proved vital. By comparing children within the same families where only some siblings were exposed to sedatives during pregnancy, researchers could isolate the true effects of the medications from other confounding influences.

The findings align with a previous US study published in JAMA Network Open in 2023, which examined 82,201 pregnancies and found no association between prenatal sedative exposure and childhood ADHD, regardless of timing or duration of use.

Filling a Critical Knowledge Gap

Evidence on the long-term neurodevelopmental safety of benzodiazepines – such as diazepam – and Z-hypnotics like zolpidem has historically been limited. This uncertainty has prompted clinical caution when prescribing these medications to pregnant women, even when they might benefit from treatment for anxiety or insomnia.

The BMJ researchers noted that even as their findings offer reassurance on neuropsychiatric safety, broader risk-benefit discussions should still occur between patients and clinicians. A BMJ editorial accompanying the study urged caution, pointing to modest elevations in some analyses that warrant further research before completely dismissing all risks.

Yet the study’s rigorous methodology strengthens confidence in its conclusions. The sibling comparison design is considered gold standard for controlling confounding factors that can skew observational research.

Room for Further Investigation

Researchers recommend additional studies to examine modest risk elevations identified in certain subgroups, especially among women using Z-hypnotics for longer periods. They stress that even as neuropsychiatric risks appear minimal, other sedative-related concerns – including dependency potential – remain relevant considerations.

The study’s scale and methodology mark a significant advance in understanding pregnancy medication safety. Previous research has often been hampered by small sample sizes or inadequate follow-up periods, limiting the reliability of conclusions about rare but serious outcomes.

Key Takeaways

• Study of 3.8 million children found no increased risk of psychiatric disorders from maternal sedative use during pregnancy
• Rigorous sibling comparison analysis eliminated apparent associations seen in initial data
• Findings align with previous US research showing no link to ADHD specifically

What This Means for Kent Residents

Pregnant women in Kent who have been prescribed sedatives for anxiety or insomnia can now discuss this reassuring BMJ evidence with their healthcare providers, potentially reducing unfounded concerns about psychiatric risks to their children. NHS Kent and Medway ICB maternity services and local GP practices follow NICE guidelines on sedative use in pregnancy, where such risk-benefit conversations routinely occur. Women should continue consulting their midwives or GPs for personalised medical advice, as broader safety considerations around sedative use – including dependency risks – still apply to treatment decisions during pregnancy.